Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.72 USD
-0.31 (-2.06%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $14.70 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Entrada Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 352 | 189 | 291 | 39 | 17 |
Receivables | 6 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 21 | 8 | 1 | 1 |
Total Current Assets | 370 | 210 | 299 | 40 | 17 |
Net Property & Equipment | 11 | 8 | 6 | 3 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 9 | 1 | 1 | 0 |
Total Assets | 469 | 252 | 306 | 44 | 18 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 6 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 8 | 6 | 2 | 1 |
Income Taxes Payable | 4 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 132 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 159 | 22 | 7 | 3 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 8 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 227 | 40 | 7 | 3 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 82 | 32 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 437 | 403 | 392 | 1 | 0 |
Retained Earnings | -195 | -188 | -94 | -43 | -16 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 242 | 213 | 299 | 40 | -16 |
Total Liabilities & Shareholder's Equity | 469 | 252 | 306 | 44 | 18 |
Total Common Equity | 242 | 213 | 299 | -41 | -47 |
Shares Outstanding | 33.30 | 31.40 | 31.20 | NA | NA |
Book Value Per Share | 7.28 | 6.77 | 9.57 | 0.00 | 0.00 |
Fiscal Year End for Entrada Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 470 | 327 | 352 | 354 | 377 |
Receivables | 8 | 78 | 6 | 5 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 9 | 12 | 24 | 10 |
Total Current Assets | 490 | 414 | 370 | 383 | 390 |
Net Property & Equipment | 11 | 11 | 11 | 11 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 7 | 7 | 7 | 4 |
Total Assets | 582 | 511 | 469 | 485 | 494 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 3 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 9 | 11 | 10 | 7 |
Income Taxes Payable | 4 | 6 | 4 | 0 | 7 |
Other Current Liabilities | 61 | 148 | 132 | 148 | 102 |
Total Current Liabilities | 86 | 174 | 159 | 165 | 126 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 10 | 9 | 8 | 11 | 96 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 152 | 241 | 227 | 238 | 287 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 547 | 441 | 437 | 433 | 429 |
Retained Earnings | -116 | -171 | -195 | -185 | -221 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 430 | 269 | 242 | 247 | 207 |
Total Liabilities & Shareholder's Equity | 582 | 511 | 469 | 485 | 494 |
Total Common Equity | 430 | 269 | 242 | 247 | 207 |
Shares Outstanding | 33.70 | 33.60 | 33.30 | 33.20 | 33.20 |
Book Value Per Share | 12.76 | 8.02 | 7.28 | 7.43 | 6.23 |